

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Complete if Known</b>	
(Use as many sheets as necessary)				<b>Application Number</b>	10/534,985
				<b>Filing Date</b>	November 10, 2003
				<b>First Named Inventor</b>	Andreas M. ZEIHER
				<b>Art Unit</b>	1641
				<b>Examiner Name</b>	Lisa V. Cook
Sheet	1	of	2	<b>Attorney Docket Number</b>	05552.1459

<b>U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS</b>					
Examiner Initials*	Cite No.	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ( <i>if known</i> )			
1	2004/0126828 A1		07-01-2004	Karumanchi et al.	
2	2006/0008829 A1		01-12-2006	Hess et al.	
3	2007/0042438 A1		02-22-2007	Zeiher et al.	
4	2009/0155827 A1		06-18-2009	Zeiher et al.	
5	2009/0163411 A1		06-25-2009	Rosendahl et al.	
6	6,391,311 B1		05-21-2002	Ferrara et al.	
7	6,455,283		09-24-2002	Ferrara et al.	

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code Number Kind Code ( <i>if known</i> )			
8	EP 1615036 A1		01-11-2006	Hoffman-LaRoche AG	
9	JP 2004-515201 T		05-27-2004	Genentech, Inc.	Counterpart
10	JP 2006-030183 A		02-02-2006	F. Hoffmann-La Roche AG	Counterpart
11	WO 98/28006 A1		07-02-1998	Cambridge University Technical Services Ltd.	
12	WO 99/47677 A2		09-23-1999	Genentech Inc.	
13	WO 03/000183 A2		01-03-2003	ImClone Systems Inc.	
14	WO 2006/045593 A1		05-04-2006	Dade Behring Marburg GmbH	
15	WO 2004/046722 A2		06-03-2004	Johann Wolfgang Goethe-Universität Frankfurt am Main	Counterpart

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation		
16	ARBOIX et al. "Acute Cerebrovascular Disease in Women" <i>Eur. Neurol.</i> 45:199-205 (2001)				
17	ATRIAL FIBRILLATION INVESTIGATORS "Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation" <i>Arch. Intern. Med.</i> 154:1449-1457 (1994)				
18	AUTIERO et al. "Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders" <i>J. Thromb. Haemostasis</i> 1:1356-1370 (2003)				
19	BELGORE et al. "sFlt-1, a Potential Antagonist for Exogenous VEGF" <i>Circulation</i> 102(15):E108-109 (2000)				

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Complete if Known</b>	
(Use as many sheets as necessary)				<b>Application Number</b>	10/534,985
				<b>Filing Date</b>	November 10, 2003
				<b>First Named Inventor</b>	Andreas M. ZEIHER
				<b>Art Unit</b>	1641
				<b>Examiner Name</b>	Lisa V. Cook
Sheet	2	of	2	<b>Attorney Docket Number</b>	05552.1459

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			Translation
	20	BLANN et al. "Vascular endothelial growth factor and its receptor, Flk-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes" <i>Clinical Science</i> 102:187-194 (2002)			
	21	CHUNG et al. "Angiogenesis in myocardial infarction" <i>Eur. Heart J.</i> 23:1604-1608 (2002)			
	22	CHUNG et al. "Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay" <i>Eur. J. Clin. Invest.</i> 33:529-535 (2003)			
	23	CORSINI et al., "New Insights Into the Pharmacodynamic and Pharmacokinetic Properties of Statins." <i>Pharmacology Therapeutics</i> , 84: 414-428 (1999)			
	24	GOETHE-UNIVERSITY FRANKFURT AM MAIN "Neuartige Diagnose von Gefäßkrankheiten soll Chancen nach Herzinfarkt verbessern: Dade Behring, Universität Frankfurt und Innovectis exklusives Lizenzabkommen" ("Novel diagnosis of vascular disease after heart attack is to improve opportunities: Dade Behring, University of Frankfurt and Innovectis to sign exclusive licensing agreement") Press Release, June 6, 2005 (German with English translation)			Yes
	25	HEESCHEN et al. "Plasma Levels of the Soluble fms-like Tyrosine Kinase 1 (VEGF receptor 1) Modulate the Prognostic Impact of Placental Growth Factor in Patients Post Myocardial Infarction" <i>Circulation</i> 110(17 Suppl.):II-411, Abstract 1942 (Oct. 26, 2004)			
	26	HEESCHEN et al. "Prognostic Value of Placental Growth Factor in Patients with Acute Chest Pain" <i>JAMA</i> 291(4435-441) (Jan. 28, 2004)			
	27	Japanese Patent Application No. 2007-537233: Notification of Reasons for Refusal; Dispatch Date: August 3, 2010 (English translation)			
	28	MAYNARD et al. "Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia" <i>J. Clin. Invest.</i> III:649-658 (2003)			
	29	NOVO et al. "Soluble CD40L and Cardiovascular Risk in Asymptomatic Low-Grade Carotid Stenosis," <i>Stroke, American Heart Association</i> , 36:673-675 (2005)			
	30	ONOUE et al. "Plasma Level of Soluble Fms-like Tyrosine Kinase 1 (sFlt1) as a Predictive Marker of Acute Severe Heart Failure in Patients with Acute Myocardial Infarction" <i>Circulation</i> 116(16 Supplement II):II-578, Abstract 2610 (Oct. 16, 2007)			
	31	SCHEUFLER et al. "Implications of Vascular Endothelial Growth Factor, sFlt-1, and sTie-2 in Plasma, Serum and Cerebrospinal Fluid During Cerebral Ischemia in Man" <i>J. Cerebral Blood Flow &amp; Metab.</i> 23:99-110 (2003)			
	32	SMITH et al. "AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients with Atherosclerotic Cardiovascular Disease: 2001 Update" <i>Circulation</i> 104:1577-1579 (2001)			
	33	WEBER et al. "Prognostische Bedeutung des löslichen PIGF Rezeptors sFlt-1 bei Patienten mit akuten Koronarsyndromen" ("Prognostic Significance of the Soluble PIGF Receptor sFlt-1 in Patients with Acute Coronary Syndrome") <i>Clin. Res. Cardiol.</i> 96(Suppl. 1)Abstract V1913 (2007) (German)			Yes
	34	WEBER et al. "Prognostic Value of the Soluble PI GF Receptor sFlt-1 in Patients Presenting with an Acute Coronary Syndrome" <i>Circulation</i> 116(16 Supplement II):II-578, Abstract 2611 (Oct. 16, 2007)			
	35	U.S. Patent Application No. 11/666,164, filed November 12, 2008, by Zeiher et al.: Office Action dated December 27, 2010			
	36	U.S. Patent Application No. 11/666,164, filed November 12, 2008, by Zeiher et al.: Office Action dated May 19, 2011			
	37	U.S. Patent Application No. 11/666,164, filed November 12, 2008, by Zeiher et al.: Examiner Interview Summary dated June 7, 2011			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.